Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

ACIP logo The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States…

More


October 2018 Draft Meeting Agenda [2 pages]

October 24-25, 2018

laptop

Registration Is Now Closed

Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Live Webcast Instructions


ACIP Recommendations


General Committee-related Information

  • Charter
    Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
  • Members
    Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
  • Articles
    Journal articles about the ACIP.

Guidance


ACIP Flyer

ACIP brochure This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?

On November 9, 2017, FDA approved a new hepatitis B vaccine, HEPLISAV-B®, for use in adults 18 years of age and older.  HEPLISAV-B® is the first licensed vaccine using a CpG adjuvant* and is administered as two doses given one month apart.  Further details on this vaccine’s approval can be found at Vaccines Licensed for Use in the United States.

*Cytosine phosphoguanine (CpG) 1018 adjuvant

June 2018 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its June 2018 meeting:

  • Reaffirmed the seasonal influenza recommendations for the 2018-2019 influenza season
  • Anthrax vaccine use for post-exposure prophylaxis in a mass vaccination campaign, including:
    • The intramuscular route of administration may be used if the subcutaneous route of administration presents clinical, operational, or logistical challenges that may delay or prevent effective vaccination
    • Should there be an inadequate supply of anthrax vaccine available for post-exposure prophylaxis, either 2 full doses or 3 half doses of anthrax vaccine absorbed (AVA) may be used to expand vaccine coverage
    • In immunocompetent adults aged 18 through 65 years, antimicrobials given in conjunction with vaccine may be discontinued at 42 days after the first vaccine dose or 2 weeks after the last vaccine dose, whichever comes later

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.


ACIP Meetings


TOP